Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
| 22.73 | |
| 22.38 | |
| - | |
| 23 | |
| 22.005 | |
| 11.39-23.72 | |
| 1 837 M | |
| 81 082 K | |
| 458 K | |
| -0.32 | |
| 0.438 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Verona Pharma plc Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May...
Tech giant Nvidia has been one of the hottest stocks over the past couple of years, with its shares more than doubling since 2022. But technology isn't the only place where investors can find excellen...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
